|Dr. Carlos Manuel Buesa Arjol||Co-Founder, Chairman, CEO & Pres||58k||N/A||N/A|
|Mr. Enric Rello||COO & CFO||N/A||N/A||N/A|
|Dr. Torsten Hoffmann||Chief Scientific Officer||N/A||N/A||1967|
|Mr. Emili Torrell||Chief Bus. Devel. Officer||N/A||N/A||N/A|
|Ms. Neus Virgili||Chief Intellectual Property Officer||N/A||N/A||N/A|
|Dr. Cesar Molinero||Chief Clinical Officer||N/A||N/A||N/A|
|Ms. Sonia Gutierrez||Chief of Clinical Operations||N/A||N/A||N/A|
|Mr. Augusto Pinel Rubio||Sec.||N/A||N/A||N/A|
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in CornellÃ de Llobregat, Spain.
Oryzon Genomics S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.